Ryabaya et al. [36] demonstrated a synergistic effect of metformin and binimetinib, showing that exposure of six melanoma cell lines, including those lacking BRAF mutations, to metformin (1 mM) and binimetinib (2 μM) resulted in at least 15% greater inhibition of cell proliferation compared to the effects of each drug used individually. The gene discussed is BRAF; the disease is melanoma.